SCHEMBL15420395

SCHEMBL15420395

Cc1cc(-c2ccc(OC[C@H]3CCOC[C@@H]3NS(C)(=O)=O)cc2)no1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.38
CXCR1 P25024 1/20 0.37
ADAM17 P78536 1/20 0.34
MAPT P10636 3/20 0.32
ALDH1A1 P00352 2/20 0.32
LMNA P02545 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CPT1A P50416 2/20 0.32
SMN1; SMN2 Q16637 3/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
ACACB O00763 1/20 0.31
PDE2A O00408 1/20 0.31
CHRM1 P11229 1/20 0.31
PDE11A Q9HCR9 1/20 0.31
IKBKE Q14164 2/20 0.31
TBK1 Q9UHD2 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12989238 0.92 XDH (0.38) XDHCXCR1ADAM17MAPTALDH1A1
SCHEMBL15441299 0.92 XDH (0.38) XDHCXCR1ADAM17MAPTALDH1A1
SCHEMBL15420861 0.91 XDH (0.38) XDHCXCR1ADAM17MAPTALDH1A1
SCHEMBL12987327 0.86 SCN9A (0.36) IKBKETBK1
SCHEMBL12986919 0.84 XDH (0.38) XDHCXCR1ADAM17MAPTALDH1A1
SCHEMBL15441644 0.84 XDH (0.38) XDHCXCR1ADAM17MAPTALDH1A1
SCHEMBL15441645 0.83 XDH (0.37) XDHCXCR1ADAM17MAPTALDH1A1
SCHEMBL12988122 0.83 XDH (0.37) XDHCXCR1ADAM17MAPTALDH1A1
SCHEMBL15420806 0.83 TP53 (0.44) XDHMAPTCHRM1TDP1
SCHEMBL15420532 0.82 HPGD (0.44) XDHMAPTALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 XDH 499/4885CXCR1 4018/4885ADAM17 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.